Biofrontera AG Stock

B8FK

DE000A4BGGM7

Pharmaceuticals

End-of-day quote Xetra Other stock markets 2024-11-29			5-day change	1st Jan Change
2.530 ^EUR	-4.71%		-6.30%	-69.96%

Nov. 30	Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
Nov. 22	Biofrontera Shares Jump After Closing Private Placement of $4.2 Million Convertible Note	MT

on all our subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions on site

News in other languages: Biofrontera AG

Biofrontera : Quartalsmitteilung zum 3. Quartal Q3/2024 (20241129 BiofronteraAG Quartalsmitteilung Q3 2024 DE)	Nov. 29
Biofrontera : Halbjahresbericht H1/2024 (20240930 HJB2024 FINAL DE)	Sep. 30
Biofrontera : Übersicht Abstimmungsergebnisse (2024 08 28 Biofrontera Abstimmung UEbersicht)	Aug. 29
Biofrontera : Einladung und Tagesordnung Hauptversammlung 2024 (Biofrontera AG Einberufung oHV 2024 de 15379259.10 )	Jul. 23
Biofrontera : Informationen nach § 125 Abs. 1 AktG i.V.m. § 125 Abs. 5 AktG, Artikel 4 Abs. 1 sowie Tabelle 3 des Anhangs der Durchführungsverordnung (EU) 2018/1212 (2024 07 16 Biofrontera Infos 125 AktG Tabelle 3 A F DVO vfin 2)	Jul. 23

More news

Course Extremes

1 week

2.35

2.69

1 month

2.35

2.95

Current year

2.15

12.18

1 year

2.15

12.18

3 years

2.15

36.33

5 years

2.15

119.07

10 years

2.15

169.47

More quotes

Managers and Directors: Biofrontera AG

Director	Title	Age	Since
María del Pilar de la Huerta Martínez DFI	Director of Finance/CFO	55	2022-09-11

Manager	Title	Age	Since
Heikki Lanckriet BRD	Director/Board Member	46	2021-12-13
Helge Lubenow CHM	Chairman	56	2024-05-09
Karlheinz Schmelig BRD	Director/Board Member	-	2021-12-13

More insiders

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Employees

Sector

Pharmaceuticals

Calendar

2025-04-23 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-02	2.350 €	-7.11%	336
24-11-29	2.530 €	-4.71%	8,828
24-11-28	2.655 €	-1.30%	24
24-11-27	2.690 €	+3.46%	4,246
24-11-26	2.600 €	-3.70%	1,105

End-of-day quote Xetra, November 28, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart BIOFRONTERA-AG

More financial data

Annual profits - Rate of surprise

Company calendar

Capitalization	14.28M 14.99M 13.28M 11.85M 21.09M 1.27B 23.21M 165M 61.25M 520M 56.31M 55.05M 2.24B	P/E ratio 2022	-1.98x	P/E ratio 2023	-40.1x
Enterprise value	12.35M 12.96M 11.49M 10.25M 18.23M 1.1B 20.06M 143M 52.95M 450M 48.68M 47.59M 1.93B	EV / Sales 2022	3.59x	EV / Sales 2023	0.73x
Free-Float	70.47%	Yield 2022 *	-	Yield 2023	-

Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 30	CI
Biofrontera Shares Jump After Closing Private Placement of $4.2 Million Convertible Note	Nov. 22	MT
Biofrontera AG announced that it has received $4.2 million in funding	Nov. 21	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $9M	Nov. 13	MT
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2024	Oct. 01	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $7.8M, vs. Street Est of $8.2M	Aug. 14	MT
Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp	Jun. 24	CI
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 31	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M	May. 15	MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11	MT
Medicus Pharma Names COO	Mar. 05	MT
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI

Biofrontera : Quarterly Report 3rd Quarter Q3/2024 (20241129 BiofronteraAG Quarterly report Q3 2024 EN)	Nov. 29	PU
Biofrontera : Half-Year Financial Report H1/2024 (20240930 HYR2024 FINAL EN)	Sep. 30	PU
Biofrontera : Voting Results (2024 08 28 Biofrontera Abstimmung UEbersicht en)	Aug. 29	PU
Biofrontera : Information in accordance with Section 125 (1) AktG in conjunction with § Section 125 (5) AktG (Information in accordance with Section 125 1 AktG)	Jul. 23	PU
Biofrontera : Proxy to the Company (Poxy to the Company AGM2024)	Jul. 23	PU

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BIOFRONTERA AG	-4.71%	-6.30%	-73.29%	-93.23%	14.99M
ELI LILLY AND COMPANY	+0.56%	+5.93%	+36.94%	+222.66%	720B
NOVO NORDISK A/S	+2.44%	+4.08%	+11.03%	+121.06%	483B
JOHNSON & JOHNSON	-0.14%	-0.63%	-2.26%	-1.46%	373B
ABBVIE INC.	-0.63%	+2.66%	+26.75%	+55.53%	321B
MERCK & CO., INC.	-1.01%	-0.54%	-2.75%	+36.16%	255B
ROCHE HOLDING AG	+0.27%	+1.07%	+6.93%	-29.51%	232B
NOVARTIS AG	-0.14%	+1.32%	+9.09%	+26.21%	210B
ASTRAZENECA PLC	-0.55%	+0.76%	+3.49%	+28.22%	207B
AMGEN INC.	-1.69%	-5.41%	+2.07%	+38.24%	149B
Average	-0.52%	+0.44%	+1.80%	+40.39%	294.98B
Weighted average by Cap.	+0.18%	+2.31%	+14.76%	+86.62%

	2022	2023
Net sales	25.74M 27.01M 23.94M 21.36M 38M 2.29B 41.83M 297M 110M 938M 101M 99.21M 4.03B	32.25M 33.84M 30M 26.76M 47.62M 2.87B 52.41M 373M 138M 1.18B 127M 124M 5.05B
Net income	-44.17M -46.35M -41.09M -36.65M -65.21M -3.93B -71.77M -510M -189M -1.61B -174M -170M -6.91B	-369K -387K -343K -306K -545K -32.82M -600K -4.26M -1.58M -13.45M -1.45M -1.42M -57.76M
Net Debt	-4.88M -5.12M -4.54M -4.05M -7.2M -434M -7.92M -56.33M -20.91M -178M -19.22M -18.79M -763M	-1.93M -2.03M -1.8M -1.61M -2.86M -172M -3.14M -22.35M -8.29M -70.48M -7.63M -7.45M -303M

Biofrontera AG Stock

Equities

B8FK

DE000A4BGGM7

Pharmaceuticals

Valuation: Biofrontera AG

Chart: Biofrontera AG

Latest news: Biofrontera AG

Press Releases: Biofrontera AG

News in other languages: Biofrontera AG

Quotes and Performance

Course Extremes

Managers and Directors: Biofrontera AG

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-4.71%
1 week	-6.30%
1 month	-11.54%
3 months	+2.02%
6 months	-17.46%
Current year	-69.96%